Recent Finacing
Recent Raise
Embera NeuroTherapeutics develops EMB-001, a metyrapone–oxazepam combination that modulates stress pathways to reduce craving and relapse, advancing Phase 1–2 programs for smoking cessation and cocaine use disorder.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
